Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
authorea preprints; 2024.
Preprint in English | PREPRINT-AUTHOREA PREPRINTS | ID: ppzbmed-10.22541.au.171010106.60491944.v1

ABSTRACT

Amubarvimab-romlusevimab is used antiviral regimens currently recommended in China for the treatment of adult patients with mild or moderate SARS-CoV-2 infections who are at a high risk factor for progression to severe COVID-19, but its exact efficacy in patients with severe COVID-19 is not yet known. This is a single-center retrospective cohort study. A total of 121 patients in intensive care units(ICU) diagnosed with severe COVID-19 were evaluated.The amubarvimab-romlusevimab therapy can reduce the 14-day mortality(23.40% vs 41.89%, p=0.037), 28-day mortality(29.79 % vs 51.35%,p=0.02), and ICU mortality(29.79% vs 55.41%,p=0.006) of severe COVID-19. To reduce bias and make the two groups balanced and comparable, a 1:1 PSM was performed. In the matched population(n=47), there were no statistically significant differences between the mAbs (monoclonal antibody)group and the Non-antiviral group in 14-day, 28-day, and thromboembolic events in COVID-19 patients. The 40-day survival analysis shows that mAbs therapy can improve patient prognosis (HR=0.45, 95%CI=0.26-0.76, p=0.008). However, no significant intergroup difference in the 40-day cumulative viral conversion rate. In a univariate Cox regression analysis, The Amubarvimab - romlusevimab therapy( HR:0.464; CI:[0.252-0.853];p:0.013),CRP, PCT, PLT, Lactate, PT, PT-INR, and pt% level at admission were risk factors for clinical prognosis. After including the above covariates, Multifactorial COX regression shows that the Amubarvimab - romlusevimab therapy( HR:0.464; CI:[0.252-0.853];p:0.013), CRP, Lactate and PT-INR at admission are independent factors for mortality of severe COVID-19. Based on the current data, we conclude that amubarvimab-romlusevimab therapy is beneficial for patients with severe COVID-19.


Subject(s)
COVID-19 , Thromboembolism , Severe Acute Respiratory Syndrome
2.
Medicine (Baltimore) ; 99(44): e22847, 2020 Oct 30.
Article in English | MEDLINE | ID: covidwho-20238619

ABSTRACT

Numerous cases of pneumonia from a novel coronavirus (SARS-CoV-2) emerged in Wuhan, China during December 2019.We determined the correlations of patient parameters with disease severity in patients with COVID-19.A total of 132 patients from Wuhan Fourth Hospital who had COVID-19 from February 1 to February 29 in 2020 were retrospectively analyzed.Ninety patients had mild disease, 32 had severe disease, and 10 had critical disease. The severe/critical group was older (P < .05), had a higher proportion of males (P < .05), and had a greater mortality rate (0% vs 61.9%, P < .05). The main symptoms were fever (n = 112, 84.8%) and cough (n = 96, 72.7%). Patients were treated with antiviral agents (n = 94, 71.2%), antibiotics (n = 92, 69.7%), glucocorticoids (n = 46, 34.8%), intravenous immunoglobulin (n = 38, 27.3%), and/or traditional Chinese medicine (n = 40, 30.3%). Patients in the severe/critical group received mechanical ventilation (n = 22, 16.7%) or high-flow nasal can-nula oxygen therapy (n = 6, 4.5%). Chest computed tomography (CT) indicated bilateral pneumonia in all patients. Relative to the mild group, the severe/critical group had higher levels of leukocytes, C-reactive protein (CRP), procalcitonin (PCT), D-dimer, B-type natriuretic peptide (BNP), liver enzymes, and myocardial enzymes (P < .05), and decreased levels of lymphocytes and blood oxygen partial pressure (P < .05).The main clinical symptoms of patients from Wuhan who had COVID-19 were fever and cough. Patients with severe/critical disease were more likely to be male and elderly. Disease severity correlated with increased leukocytes, CRP, PCT, BNP, D-dimer, liver enzymes, and myocardial enzymes, and with decreased lymphocytes and blood oxygen partial pressure.


Subject(s)
Coronavirus Infections/epidemiology , Pneumonia, Viral/epidemiology , Adult , Aged , Betacoronavirus/isolation & purification , COVID-19 , China/epidemiology , Coronavirus Infections/blood , Coronavirus Infections/therapy , Female , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/blood , Pneumonia, Viral/therapy , Retrospective Studies , SARS-CoV-2
3.
Environ Sci Pollut Res Int ; 30(19): 54993-55008, 2023 Apr.
Article in English | MEDLINE | ID: covidwho-20245400

ABSTRACT

Environmental regulation restricts corporate pollution emissions and affects corporate investment decisions and asset allocation. Based on the data of A-share listed enterprises in China from 2013 to 2021 and the difference in differences (DID) model, this paper identifies the impact of environmental regulation on corporate financialization with the help of the "Blue Sky Protection Campaign (2018-2020)" (BSPC) of China. The results indicate that environmental regulation has a crowding-out effect on corporate financialization. Enterprises with stricter financing constraints receive more significant crowding-out effects. This paper provides a new perspective on the "Porter hypothesis." Under the constraint of financial resources and high environmental protection costs, enterprises carry out innovative activities and environmental protection investments by consuming financial assets to reduce the risk of environmental violations. The government's environmental regulation is an effective way to guide the financial development of enterprises, control environmental pollution, and promote enterprise innovation.


Subject(s)
Environmental Pollution , Investments , China , Organizations , Conservation of Natural Resources
4.
Lancet Infect Dis ; 2023 May 19.
Article in English | MEDLINE | ID: covidwho-2327135

ABSTRACT

BACKGROUND: Heterologous boosting is suggested to be of use in populations who have received inactivated COVID-19 vaccines. We aimed to assess the safety and immunogenicity of a heterologous vaccination with the mRNA vaccine CS-2034 versus the inactivated BBIBP-CorV as a fourth dose, as well as the efficacy against the SARS-CoV-2 omicron (BA.5) variant. METHODS: This trial contains a randomised, double-blind, parallel-controlled study in healthy participants aged 18 years or older (group A) and an open-label cohort in participants 60 years and older (group B), who had received three doses of inactivated whole-virion vaccines at least 6 months before enrolment. Pregnant women and people with major chronic illnesses or a history of allergies were excluded. Eligible participants in group A were stratified by age (18-59 years and ≥60 years) and then randomised by SAS 9.4 in a ratio of 3:1 to receive a dose of the mRNA vaccine (CS-2034, CanSino, Shanghai, China) or inactivated vaccine (BBIBP-CorV, Sinopharm, Beijing, China). Safety and immunogenicity against omicron variants of the fourth dose were evaluated in group A. Participants 60 years and older were involved in group B for safety observations. The primary outcome was geometric mean titres (GMTs) of the neutralising antibodies against omicron and seroconversion rates against BA.5 variant 28 days after the boosting, and incidence of adverse reactions within 28 days. The intention-to-treat group was involved in the safety analysis, while all patients in group A who had blood samples taken before and after the booster were involved in the immunogenicity analysis. This trial was registered at the Chinese Clinical Trial Registry Centre (ChiCTR2200064575). FINDINGS: Between Oct 13, and Nov 22, 2022, 320 participants were enrolled in group A (240 in the CS-2034 group and 80 in the BBIBP-CorV group) and 113 in group B. Adverse reactions after vaccination were more frequent in CS-2034 recipients (158 [44·8%]) than BBIBP-CorV recipients (17 [21·3%], p<0·0001). However, most adverse reactions were mild or moderate, with grade 3 adverse reactions only reported by eight (2%) of 353 participants receiving CS-2034. Heterologous boosting with CS-2034 elicited 14·4-fold (GMT 229·3, 95% CI 202·7-259·4 vs 15·9, 13·1-19·4) higher concentration of neutralising antibodies to SARS-CoV-2 omicron variant BA.5 than did homologous boosting with BBIBP-CorV. The seroconversion rates of SARS-CoV-2-specific neutralising antibody responses were much higher in the mRNA heterologous booster regimen compared with BBIBP-CorV homologous booster regimen (original strain 47 [100%] of 47 vs three [18·8%] of 16; BA.1 45 [95·8%] of 48 vs two [12·5%] 16; and BA.5 233 [98·3%] of 240 vs 15 [18·8%] of 80 by day 28). INTERPRETATION: Both the administration of mRNA vaccine CS-2034 and inactivated vaccine BBIBP-CorV as a fourth dose were well tolerated. Heterologous boosting with mRNA vaccine CS-2034 induced higher immune responses and protection against symptomatic SARS-CoV-2 omicron infections compared with homologous boosting, which could support the emergency use authorisation of CS-2034 in adults. FUNDING: Science and Technology Commission of Shanghai, National Natural Science Foundation of China, Jiangsu Provincial Science Fund for Distinguished Young Scholars, and Jiangsu Provincial Key Project of Science and Technology Plan. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

5.
Front Microbiol ; 14: 1043967, 2023.
Article in English | MEDLINE | ID: covidwho-2254595

ABSTRACT

Sequencing technology is the most commonly used technology in molecular biology research and an essential pillar for the development and applications of molecular biology. Since 1977, when the first generation of sequencing technology opened the door to interpreting the genetic code, sequencing technology has been developing for three generations. It has applications in all aspects of life and scientific research, such as disease diagnosis, drug target discovery, pathological research, species protection, and SARS-CoV-2 detection. However, the first- and second-generation sequencing technology relied on fluorescence detection systems and DNA polymerization enzyme systems, which increased the cost of sequencing technology and limited its scope of applications. The third-generation sequencing technology performs PCR-free and single-molecule sequencing, but it still depends on the fluorescence detection device. To break through these limitations, researchers have made arduous efforts to develop a new advanced portable sequencing technology represented by nanopore sequencing. Nanopore technology has the advantages of small size and convenient portability, independent of biochemical reagents, and direct reading using physical methods. This paper reviews the research and development process of nanopore sequencing technology (NST) from the laboratory to commercially viable tools; discusses the main types of nanopore sequencing technologies and their various applications in solving a wide range of real-world problems. In addition, the paper collates the analysis tools necessary for performing different processing tasks in nanopore sequencing. Finally, we highlight the challenges of NST and its future research and application directions.

6.
J Med Internet Res ; 25: e44225, 2023 02 17.
Article in English | MEDLINE | ID: covidwho-2236840

ABSTRACT

BACKGROUND: Despite the increased development and use of mobile health (mHealth) devices during the COVID-19 pandemic, there is little knowledge of willingness of the Chinese people to use mHealth devices and the key factors associated with their use in the post-COVID-19 era. Therefore, a more comprehensive and multiangle investigation is required. OBJECTIVE: We aimed to probe Chinese attitudes regarding the use of mHealth and analyze possible associations between the attitude of willingness to use mHealth devices and some factors based on the socioecological model. METHODS: A survey was conducted using quota sampling to recruit participants from 148 cities in China between June 20 and August 31, 2022. Data from the survey were analyzed using multiple stepwise regression to examine the factors associated with willingness to use mHealth devices. Standardized regression coefficients (ß) and 95% CIs were calculated using multiple stepwise regression. RESULTS: The survey contained a collection of 21,916 questionnaires and 21,897 were valid questionnaires, with a 99.91% effective response rate. The median score of willingness to use mHealth in the post-COVID-19 era was 70 points on a scale from 0 to 100. Multiple stepwise regression results showed that the female gender (ß=.03, 95% CI 1.04-2.35), openness personality trait (ß=.05, 95% CI 0.53-0.96), higher household per capita monthly income (ß=.03, 95% CI 0.77-2.24), and commercial and multiple insurance (ß=.04, 95% CI 1.77-3.47) were factors associated with the willingness to use mHealth devices. In addition, people with high scores of health literacy (ß=.13, 95% CI 0.53-0.68), self-reported health rating (ß=.22, 95% CI 0.24-0.27), social support (ß=.08, 95% CI 0.40-0.61), family health (ß=.03, 95% CI 0.03-0.16), neighbor relations (ß=.12, 95% CI 2.09-2.63), and family social status (ß=.07, 95% CI 1.19-1.69) were more likely to use mHealth devices. CONCLUSIONS: On the basis of the theoretical framework of socioecological model, this study identified factors specifically associated with willingness of the Chinese people to use mHealth devices in the post-COVID-19 era. These findings provide reference information for the research, development, promotion, and application of future mHealth devices.


Subject(s)
COVID-19 , Telemedicine , Humans , Female , COVID-19/epidemiology , Cross-Sectional Studies , Pandemics , China , Telemedicine/methods
7.
Zhongguo Dang Dai Er Ke Za Zhi ; 24(12): 1295-1300, 2022 Dec 15.
Article in Chinese | MEDLINE | ID: covidwho-2203145

ABSTRACT

OBJECTIVES: To study the features of unintentional injury in children under the impact of coronavirus disease 2019 (COVID-19). METHODS: A retrospective analysis was performed on the medical data of 2 526 children with unintentional injury in Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from July 2019 to June 2022. The study period was divided into 5 stages: before the epidemic (July to December, 2019), the Wuhan epidemic period (January to April, 2020), the epidemic remission period in China (May 2020 to February 2022), the Shanghai epidemic period (March to May, 2022), and the epidemic remission period in Shanghai (June 2022). The incidences of unintentional injury in children at different time stages and different ages were compared. A questionnaire survey was conducted on 107 children of the 2 526 children to explore the features of unintentional injury. RESULTS: There were significant differences in gender composition, age, age distribution and proportion of many types of unintentional injuries among the five time stages (P<0.05). There was a reduction in the number of children who attended the emergency department due to unintentional injury during the Wuhan epidemic and the Shanghai epidemic. The proportion of children with trauma-related unintentional injuries in each stage reached more than 50%, and the proportion of children with trauma-related unintentional injuries reached 63.9% and 82.0%, respectively during the Wuhan epidemic and the Shanghai epidemic. Most children suffering from unintentional injury were mainly school-aged and preschool children (1 823 children, 72.17%). Compared with the same period of Shanghai epidemic in 2021, the age of children with unintentional injury was younger (median 7 years vs 11 years), and the proportion of children with trauma-related unintentional injuries increased (97% vs 69%) during the Shanghai epidemic (P<0.05). CONCLUSIONS: Under the COVID-19 epidemic, there is a reduction in the number of children with unintentional injury, while there is an increase in the proportion of children with trauma-related unintentional injuries. Unintentional injury is more common among school-aged and preschool children.


Subject(s)
COVID-19 , Epidemics , Wounds and Injuries , Child, Preschool , Humans , Child , COVID-19/epidemiology , Retrospective Studies , China/epidemiology , Schools , Wounds and Injuries/epidemiology , Wounds and Injuries/etiology
8.
Int J Gen Med ; 15: 8353-8363, 2022.
Article in English | MEDLINE | ID: covidwho-2154472

ABSTRACT

Coronavirus disease 2019 (COVID-19) remains an uncontained, worldwide pandemic. While battling the disease in China, the Chinese government has actively promoted the use of traditional Chinese medicine, and many studies have been conducted to determine the efficacy of traditional Chinese medicine for treating COVID-19. The present review discusses the effectiveness and safety of traditional Chinese medicine in curing COVID-19 and provides clinical evidence from all confirmed cases in China. Applications of traditional Chinese medicine and specific recipes for treating other viral infections, such as those caused by severe acute respiratory syndrome coronavirus and influenza A viruses (including H1N1), are also discussed. Studies have reported that traditional Chinese medicine treatment plays a significant role in improving clinical symptoms. Therefore, further investigation may be of high translational value in revealing novel targeted therapies for COVID-19.

9.
J Environ Chem Eng ; 10(6): 108697, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2131437

ABSTRACT

The sudden outbreak of coronavirus disease (COVID-19) triggered by SARS-CoV-2 infection has created a terrifying situation around the world. The spike protein of SARS-CoV-2 can act as an early biomarker for COVID-19. Therefore, controlling the spread of COVID-19 requires a low-cost, fast-response, and sensitive monitoring technique of spike protein. Herein, a photoelectrochemical (PEC) immunosensor for the detection of spike protein was constructed using the nanobody and an Mn (Ⅱ) modified graphitic carbon nitride (Mn/g-C3N4). The introduction of atomically dispersed Mn (Ⅱ) can accelerate the effective transfer and separation of photogenerated electron-hole pairs, which significantly boosts PEC performance of g-C3N4, thereby improving the detection sensitivity. As a recognition site, nanobody can achieve high-affinity binding to the spike protein, leading to a high sensitivity. The linear detection range of the proposed PEC immunosensor was 75 fg mL-1 to 150 pg mL-1, and the limit of detection was calculated to be 1.22 fg mL-1. This stable and feasible PEC immunosensor would be a promising diagnostic tool for sensitively detecting spike protein of SARS-CoV-2.

10.
Heliyon ; 2022.
Article in English | EuropePMC | ID: covidwho-2047078

ABSTRACT

Objective The incidence of post-traumatic stress disorder (PTSD) increased among healthcare workers (HCWs) during the outbreak of COVID-19. The purpose of this study was to examine the relationship between eating behavior and PTSD, considering the mediation effect of anxiety, depression and sleep. Methods A total of 101 HCWs completed a survey. The Food-Frequency Questionnaires (FFQ) were used to evaluate the diet. A special survey was conducted on the eating time of each shift mode. The PTSD Checklist-Civilian Version (PCL-C), Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), Pittsburgh Sleep Quality Index (PSQI), and Morning-Evening Questionnaire (MEQ) were utilized to assess clinical symptoms. Results There was a statistically significant correlation between the night shift eat midpoint (NEMP) and PTSD symptoms, anxiety and depression as significant mediators. The last meal jet lag between night shift and day shift (NDLM) was related to PTSD symptoms significantly, and sleep and anxiety were significant mediators. The relationship between animal-based protein pattern and PTSD symptoms was statistically significant, and anxiety was the significant mediator. Conclusions The earlier the HCWs eat in the night shift, the lighter the symptoms of PTSD. This is mediated by improving anxiety, depression and sleep disorder. Furthermore, the consumption of animal protein could reduce symptoms of PTSD by improving anxiety. COVID-19;Eating behavior;Sleep disorder;Anxiety;Depression;PTSD;Mediation analysis.

11.
Frontiers in cellular and infection microbiology ; 12, 2022.
Article in English | EuropePMC | ID: covidwho-2046017

ABSTRACT

Since the end of 2019, COVID-19 caused by SARS-CoV-2 has spread worldwide, and the understanding of the new coronavirus is in a preliminary stage. Currently, immunotherapy, cell therapy, antiviral therapy, and Chinese herbal medicine have been applied in the clinical treatment of the new coronavirus;however, more efficient and safe drugs to control the progress of the new coronavirus are needed. Long noncoding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs) may provide new therapeutic targets for novel coronavirus treatments. The first aim of this paper is to review research progress on COVID-19 in the respiratory, immune, digestive, circulatory, urinary, reproductive, and nervous systems. The second aim is to review the body systems and potential therapeutic targets of lncRNAs, miRNAs, and circRNAs in patients with COVID-19. The current research on competing endogenous RNA (ceRNA) (lncRNA-miRNA-mRNA and circRNA-miRNA-mRNA) in SARS-CoV-2 is summarized. Finally, we predict the possible therapeutic targets of four lncRNAs, MALAT1, NEAT1, TUG1, and GAS5, in COVID-19. Importantly, the role of PTEN gene in the ceRNA network predicted by lncRNA MALAT1 and lncRNA TUG1 may help in the discovery and clinical treatment of effective drugs for COVID-19.

12.
Journal of environmental chemical engineering ; 2022.
Article in English | EuropePMC | ID: covidwho-2045783

ABSTRACT

The sudden outbreak of coronavirus disease (COVID-19) triggered by SARS-CoV-2 infection has created a terrifying situation around the world. The Spike protein of SARS-CoV-2 may act as an early biomarker for leading to receptor binding and virus entry. Therefore, controlling the spread of COVID-19 requires a low-cost, fast-response, and sensitive monitoring technique of spike protein. Herein, a photoelectrochemical (PEC) immunosensor for the detection of spike protein was constructed using the nanobody and an Mn (Ⅱ) modified graphitic carbon nitride (Mn/g-C3N4). The introduction of atomically dispersed Mn (Ⅱ) accelerates the effective transfer and separation of photogenerated electron-hole pairs, which significantly boosts PEC performance of g-C3N4, thereby improving the detection sensitivity. As a recognition site, nanobody can achieve high-affinity binding to the spike protein for detection. The linear detection range of the proposed PEC immunosensor was 75 fg mL–1 to 150 pg mL–1, and the limit of detection was calculated to be 1.22 fg mL–1. This stable and feasible PEC immunosensor is a promising diagnostic tool for sensitively detecting SARS-CoV-2 spike protein. Graphical

13.
Front Pharmacol ; 13: 984981, 2022.
Article in English | MEDLINE | ID: covidwho-2029976

ABSTRACT

Therapies based on orally administrated nucleic acids have significant potential for the treatment of infectious diseases, including chronic inflammatory diseases such as inflammatory bowel disease (IBD)-associated with the gastrointestinal (GI) tract, and infectious and acute contagious diseases like coronavirus disease 2019 (COVID-19). This is because nucleic acids could precisely regulate susceptibility genes in regulating the pro- and anti-inflammatory cytokines expression related to the infections. Unfortunately, gene delivery remains a major hurdle due to multiple intracellular and extracellular barriers. This review thoroughly discusses the challenges of nanoparticle-based nucleic acid gene deliveries and strategies for overcoming delivery barriers to the inflammatory sites. Oral nucleic acid delivery case studies were also present as vital examples of applications in infectious diseases such as IBD and COVID-19.

14.
ACS Omega ; 7(34): 30321-30332, 2022 Aug 30.
Article in English | MEDLINE | ID: covidwho-2016551

ABSTRACT

Using surface-initiated atom transfer radical polymerization (ATRP), block polymers with a series of quaternization degrees were coated on the surface of silica nanocapsules (SNCs) by the "grafting-from" technique. Molnupiravir, an antiviral medicine urgently approved for the treatment of SARS-CoV-2, was encapsulated in polymer-coated SNCs and further incorporated into well-defined films with polystyrene sulfonate (PSS) homopolymers by layer-by-layer (LBL) self-assembly via electrostatic interactions. We investigated the impact of the quaternization degree of the polymers and steric hindrance of functional groups on the growth mode, swelling/deswelling transition, and drug-delivering efficiency of the obtained LBL films. The SNCs were derived from coronas of parent block polymers of matched molecular weights-poly(N-isopropylacrylamide)-block-poly(N,N-dimethylaminoethyl methacrylate) (PNIPAM-b-PDMAEMA)-by quaternization with methyl sulfate. As revealed by the data results, SNCs with coronas with higher quaternization degrees resulted in a larger layering distance of the film structure because of weaker ionic pairing (due to the presence of a bulky methyl spacer) between SNCs and PSS. Interestingly, when comparing the drug release profile of the encapsulated drugs from SNC-based films, the release rate was slower in the case of capsule coronas with higher quaternization degrees because of the larger diffusion distance of the encapsulated drugs and stronger hydrophobic-hydrophobic interactions between SNCs and drug molecules.

15.
Acta Pharmaceutica Sinica ; 57(4):917-930, 2022.
Article in Chinese | GIM | ID: covidwho-1975501

ABSTRACT

Histone deacetylases (HDACs) are a class of key enzymes that regulate epigenetics. There are 5 small-molecule HDACs inhibitors having been approved for anti-cancer therapy on the market. In recent years, there have been more and more studies on the antiviral aspects of HDACs inhibitors. This article classifies viruses into human immunodeficiency virus 1 (HIV-1), new coronavirus (SARS-CoV-2), Epstein-Barr virus (EBV) and other viruses, systematically summarizes the recent advances of antiviral effects of the HDACs inhibitors from the perspective of medicinal chemistry. This review aims to provide the researchers the convenience of accessing the latest advances of the antiviral effects of HDACs inhibitors, and to analyze the challenges and prospects of this field in future drug discovery.

16.
World J Clin Cases ; 10(22): 7968-7972, 2022 Aug 06.
Article in English | MEDLINE | ID: covidwho-1969803

ABSTRACT

BACKGROUND: Patients diagnosed with non-small-cell lung cancer with activated epidermal growth factor receptor mutations are more likely to develop leptomeningeal (LM) metastasis than other types of lung cancers and have a poor prognosis. Early diagnosis and effective treatment of leptomeningeal carcinoma can improve the prognosis. CASE SUMMARY: A 55-year-old female with a progressive headache and vomiting for one month was admitted to Peking University First Hospital. She was diagnosed with lung adenocarcinoma with osseous metastasis 10 months prior to admittance. epidermal growth factor receptor (EGFR) mutation was detected by genomic examination, so she was first treated with gefitinib for 10 months before acquiring resistance. Cell-free cerebrospinal fluid (CSF) circulating tumor DNA detection by next-generation sequencing was conducted and indicated the EGFR-Thr790Met mutation, while biopsy and cytology from the patient's CSF and the first enhanced cranial magnetic resonance imaging (MRI) showed no positive findings. A month later, the enhanced MRI showed linear leptomeningeal enhancement, and the cytology and biochemical examination in CSF remained negative. Therefore, osimertinib (80 mg/d) was initiated as a second-line treatment, resulting in a good response within a month. CONCLUSION: This report suggests clinical benefit of osimertinib in LM patients with positive detection of the EGFR-Thr790Met mutation in CSF and proposes that the positive findings of CSF circulating tumor DNA as a liquid biopsy technology based on the detection of cancer-associated gene mutations may appear earlier than the imaging and CSF findings and may thus be helpful for therapy. Moreover, the routine screening of chest CT with the novel coronavirus may provide unexpected benefits.

17.
Sustainability ; 14(9):5365, 2022.
Article in English | MDPI | ID: covidwho-1820376

ABSTRACT

Tourism and hospitality have been recognized as leading economic sectors globally. Before the outbreak of COVID-19, it was estimated that the tourism and hospitality sector was growing by around 4% each year. Although the economic-efficiency-led hypothesis of the tourism and hospitality sector is strong, there is another perspective related to tourism and hospitality. That is, tourism and hospitality are not as 'green';as they were supposed to be. Indeed, this sector is known for its outsized carbon footprint. It is estimated that, if not managed efficiently, the GHG contribution of the tourism sector will grow in the future. Specifically, the hotel business accounts for 1% of total global greenhouse gas emissions (GHG), which is huge. Responding to these significant issues, this study investigates the relationship between the corporate social responsibility (CSR) activities of a hotel enterprise and employees' pro-environmental behavior (PEB). The mediating role of environmental-specific transformational leadership (ESTFL) and the moderating role of green perceived organizational support (GPOS) were also tested in the above relationship. The data were collected by the employees through a self-administered questionnaire. The hypothesized relations were statistically investigated by using structural equation modeling (SEM). The findings revealed that CSR activities of a hotel not only influence employees' PEB directly, but the mediating role of ESTFL was also significant. At the same time, the conditional indirect role of GPOS was also confirmed. This study offers different theoretical and practical insights, which have been discussed in detail.

18.
Anal Chim Acta ; 1211: 339904, 2022 Jun 08.
Article in English | MEDLINE | ID: covidwho-1819418

ABSTRACT

Until now, COVID-19 caused by SARS-CoV-2 is engulfing the worldwide and still ranging to date, continuing to threaten the public health. The main challenge facing COVID-19 epidemic is short of fast-response and high-efficiency methods to determine SARS-CoV-2 viral pathogens. Herein, a nanobody-based label-free photoelectrochemical (PEC) immunosensor has been fabricated for rapidly detecting SARS-CoV-2 spike protein. As a small-size and high-stability antibody, nanobody was directly and well immobilized with Au nanoparticles and TiO2 spheres by the interaction. Au deposited TiO2 nanomaterial possessed 8.5 times photoelectric performance in comparison with TiO2 in the presence of electron donor owing to surface plasma resonance effect of Au. Based on the steric hindrance effect, this immunoassay platform realized the linear detection from 0.015 to 15000 pg mL-1, and a limit of detection was low as 5 fg mL-1. The label-free PEC immunoassay design provides a new idea for convenient, rapid, and efficient test of SARS-CoV-2 spike protein and broadens further application of nanobody as an identification agent to specific biomarkers.


Subject(s)
Biosensing Techniques , COVID-19 , Metal Nanoparticles , Biosensing Techniques/methods , COVID-19/diagnosis , Electrochemical Techniques/methods , Gold , Humans , Immunoassay/methods , Limit of Detection , SARS-CoV-2 , Spike Glycoprotein, Coronavirus
19.
Journal of Destination Marketing & Management ; : 100705, 2022.
Article in English | ScienceDirect | ID: covidwho-1799853

ABSTRACT

Crowding used to be a double-edged sword in the tourism industry. However, the COVID-19 pandemic seems to make the disadvantage of crowding more obvious. Here, we investigated the relationship between vaccination status (including vaccination completeness and willingness), crowding perception, popular perception, destination attractiveness, and loyalty based on the Stimulus-Organism-Response model. Empirical research data were collected through a survey of 535 tourists to Nanjing's Confucian Temple, China, which is known for its tremendous travel volume. The results show that both crowding perception and popular perception significantly affect loyalty, but with opposite signs. Moreover, if tourists have been vaccinated, the positive effect of destination attractiveness on loyalty will intensify, meaning that the rarely investigated variable vaccination status indeed plays a moderating role.

20.
medrxiv; 2022.
Preprint in English | medRxiv | ID: ppzbmed-10.1101.2022.01.13.22269198

ABSTRACT

The ongoing coronavirus disease 2019 (COVID-19) pandemic has pushed the world in the face of another huge outbreak. In order to have a better understanding on the fast transmission of Omicron variant, we made seasonal predictions on the development of Omicron pandemic globally, as well as 11 key countries. The results demonstrated that the pandemic has an exponential-like growth rate at the initial stage of the outbreak, and will have small resurgences around April and June in north hemisphere countries and south hemisphere countries, respectively.


Subject(s)
Coronavirus Infections , COVID-19
SELECTION OF CITATIONS
SEARCH DETAIL